← All trials
NCT03849469
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2019
- Primary completion
- Sep 30, 2026
- Completion date
- Mar 31, 2027
- First posted
- —
- Last posted
- —
- Enrollment
- 242
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Nasopharyngeal Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Hamartoma
- Carcinoma, Hepatocellular
- Melanoma
- Neoplasms
- Pancreatic Neoplasms
- Penile Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Vulvar Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Cholangiocarcinoma
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.